• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:刘磊,荣一丞,刘欣雨,杨乐,陈黎明.藏药然那桑培丸对稳定动脉粥样硬化斑块的作用及机制[J].药学研究,2025,44(4):340-344[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2825次   下载 785次 本文二维码信息
码上扫一扫!
藏药然那桑培丸对稳定动脉粥样硬化斑块的作用及机制
刘磊1,荣一丞2,刘欣雨1,杨乐1,陈黎明1,3
字体:加大+|默认|缩小-
(1.山东第一医科大学附属省立医院心内科,山东 济南 250021;2.南京大学生命科学院,江苏 南京 210023;3.海北藏族自治州第二人民医院,青海 海北 810399)
摘要:
目的 探讨藏药然那桑培丸(Rannasangpei,RNSP)在干预动脉粥样硬化斑块中的作用及其相关机制。方法 选用6-8周龄的雄性载脂蛋白E敲除(Apolipoprotein E-knocknout, ApoE-/-)小鼠,采用高脂饲料喂养以建立动脉粥样硬化模型。将成功建模的小鼠随机分为模型组(仅饲喂高脂饲料)、阿托伐他汀(Atorvastatin)组(阿托伐他汀(10mg/kg·d)灌胃给药)、RNSP组(然那桑培丸(7 mg/kg·d)灌胃给药),每组10只。通过油红O染色评估主动脉粥样硬化面积和主动脉根部斑块横截面积、斑块内的脂质成分。天狼猩红染色用于评估胶原成分。CD68、α-SMA免疫组化分别用于定量分析巨噬细胞、平滑肌成分。此外,我们计算了不同组别小鼠的斑块易损指数。结果 模型组、RNSP组、Atorvastatin组的初始体重无统计学差异(P>0.05)。与模型组相比,Atorvastatin组呈现预期血脂调控效应,而RNSP组未显示显著血脂改善;RNSP组与Atorvastatin组主动脉弓病变呈显著缓解趋势;RNSP组与Atorvastatin组动脉硬化病变面积显著缩减(P<0.05)。在脂质沉积减少方面,Atorvastatin的调控作用优于RNSP。在降低巨噬细胞浸润方面,RNSP的调控作用优于Atorvastatin。且与模型组相比,RNSP组与Atorvastatin组都能显著提升斑块结构稳定性,并显著降低斑块的易损指数(P<0.05)。结论 藏药然那桑培丸可通过多靶点调控发挥抗动脉粥样硬化作用,为藏医药临床转化提供新的科学依据和理论支持。
关键词:  动脉粥样硬化斑块  然那桑培丸  多靶点调控
DOI:10.13506/j.cnki.jpr.2025.04.005
基金项目:山东省自然科学基金项目(No.ZR2020MH028);山东省医药卫生科技发展计划项目(No.2019WS509);藏药然那桑培丸稳定动脉粥样硬化斑块机制研究项目(山东省对口支援青海干部管理组);芫根提取物对于高原性肺动脉高压作用及其研究项目(山东省对口支援青海干部管理组)
出版日期:2025-04-25
Study on the effect and mechanism of Tibetan Medicine Rannasangpei in stabilizing atherosclerotic Plaques
LIU Lei1,RONG Yicheng2,LIU Xinyu1,YANG Le1,CHEN Liming1,3
(1.Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China;2. Nanjing University School of Life Sciences, Nanjing 210023, China;3. The Second People's Hospital of Haibei Tibetan Autonomous Prefecture, Haibei 810399, China)
Abstract:
Objective To investigate the role and mechanism of the Tibetan medicine Rannasangpei (RNSP) in stabilizing atherosclerotic plaques. Methods Male Apolipoprotein E-knocknout (ApoE-/-) mice aged 6-8 weeks (body weight 20±2 g) were fed a high-fat diet to establish atherosclerotic models. ApoE-/- male mice fed with normal diet were taken as blank control group (n=10), and the established atherosclerotic models mice were randomly divided into model group (fed with high-fat diet, n=10), Atorvastatin group (10 mg/kg·d atorvastatin administered intragastrically, n=10) and RNSP group (7 mg/kg·d RNSP administered intragastrically, n=10).. The atherosclerotic area of aorta, the cross-sectional area of aortic root plaque and the lipid composition in plaque were estimated by oil red O staining. Sirius red staining was used to evaluate collagen composition. CD68 and α-SMA immunohistochemistry were used to quantitatively analyze the components of macrophages and smooth muscle, respectively. In addition, we calculated the plaque vulnerability index of different groups of mice.Results No significant difference in initial weight among model group, RNSP group and Atorvastatin group (P>0.05). Compared with the model group, Atorvastatin group showed the expected blood lipid regulation effect, while RNSP group did not show significant blood lipid improvement; the aortic arch lesions in RNSP group and Atorvastatin group showed a significant remission trend; the area of atherosclerotic lesions in RNSP group and Atorvastatin group was significantly reduced (P<0.05). In the aspect of reducing lipid deposition, the regulatory effect of Atorvastatin was better than RNSP. In the aspect of reducing macrophage infiltration, RNSP had a better regulatory effect than Atorvastatin. Compared with the model group, RNSP and Atorvastatin groups significantly improved the structural stability of plaque and significantly reduced the vulnerability index of plaque (P<0.05).Conclusion The Tibetan medicine RNSP could exert its anti-atherosclerosis effect through multi-target regulation, providing new scientific basis and theoretical support for the clinical transformation of Tibetan medicine.
Key words:  Atherosclerotic plaque  Rannasangpei  Multi-target regulation
今日访问量:2643    总访问量:55339157
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司